Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 11/20 | 0.78 |
| ▸ | TOP1 | P11387 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | CRHBP | P24387 | 1/20 | 0.68 |
| ▸ | CASP7 | P55210 | 1/20 | 0.68 |
| ▸ | CASP6 | P55212 | 1/20 | 0.68 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14172134 | 0.89 | NQO1 (0.68) | NQO1TOP1MEN1KMT2ACYP2C9 | |
| SCHEMBL4385323 | 0.88 | NQO1 (1.00) | NQO1TOP1MEN1KMT2ACYP2C9 | |
| SCHEMBL7355113 | 0.86 | NQO1 (0.94) | NQO1TOP1MEN1KMT2ACYP2C9 | |
| SCHEMBL7896856 | 0.86 | NQO1 (1.00) | NQO1TOP1MEN1KMT2ACYP2C9 | |
| SCHEMBL310481 | 0.86 | VKORC1 (0.82) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL14078661 | 0.86 | NQO1 (0.73) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL32659670 | 0.86 | VKORC1 (0.82) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL7355322 | 0.85 | VKORC1 (0.74) | NQO1TOP1MEN1KMT2ACYP2C9 | |
| SCHEMBL14172083 | 0.84 | NQO1 (1.00) | NQO1TOP1MEN1KMT2ACYP2C9 | |
| SCHEMBL19966048 | 0.83 | NQO1 (0.57) | NQO1TOP1MEN1KMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3277692-B1 | COUMARIN DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL COMPOSITION THEREOF, ITS PREPARATION AND USE | I NOVA MEDICINSKA ISTRAZIVANJA D O O (HR) | 2019-09-11 | — | — | EP | disclosed |
| US-10266545-B2 | Coumarin derivative as antiviral agent, pharmaceutical composition thereof, its preparation and use | I-NOVA MEDICINSKA ISTRAZIVANJA D.O.O. (HR) | 2019-04-23 | — | — | US | disclosed |
| US-20180072752-A1 | COUMARIN DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL COMPOSITION THEREOF, ITS PREPARATION AND USE | I-NOVA MEDICINSKA ISTRAZIVANJA D.O.O. (HR) | 2018-03-15 | — | — | US | disclosed |
| US-20180072752-A1 | COUMARIN DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL COMPOSITION THEREOF, ITS PREPARATION AND USE | I-NOVA MEDICINSKA ISTRAZIVANJA D.O.O. (HR) | 2018-03-15 | — | — | US | disclosed |
| WO-2016156888-A1 | COUMARIN DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL COMPOSITION THEREOF, ITS PREPARATION AND USE | I-NOVA MEDICINSKA ISTRAZIVANJA D.O.O. (HR) | 2016-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072752-A1 | COUMARIN DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL COMPOSITION THEREOF, ITS PREPARATION AND USE | CYP3A7, MAVS, SARS1 | NQO1 609/4885TOP1 775/4885MEN1 3224/4885 |
| US-10266545-B2 | Coumarin derivative as antiviral agent, pharmaceutical composition thereof, its preparation and use | CYP3A7, MAVS, SARS1 | NQO1 609/4885TOP1 775/4885MEN1 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.